Valvular & structural heart disease
Tricuspid Regurgitation and 3-Year Mortality After Transseptal Mitral Valve-in-Valve Replacement
Authors' conclusion
Preprocedural severe or greater TR, 30-day residual severe or greater TR, and unchanged or worsened TR after transseptal MViV were associated with a significantly increased risk for 3-year all-cause mortality.
Study context
- Population
- Patients undergoing transseptal mitral valve-in-valve replacement, STS/ACC TVT Registry, 2015–20244,938 met inclusion criteria
- Participants
- 5,971 patients
- Exposure
- Severe or greater tricuspid regurgitation (TR) vs moderate vs mild or less TR before transseptal mitral valve-in-valve (MViV)
- Severe or greater TRn = 1,039
- Outcome
- All-cause mortality
- Follow-up
- 3 years
Methodological detailspropensity-score matched, 513 sites
- Propensity-score matched
- 513 sites
Main finding
As reported in the abstract
3-year mortality by baseline TR
P = 0.004
Observational data: associations, not effects.
Further findings
| Outcome | Moderate TR | P value |
|---|---|---|
| 3-year mortality by residual TR at 30 days · 3 yearsResidual severe or greater TR vs Moderate or less TR | 30.7% | P = 0.04 |
- ≥1-grade TR improvement at 30 days (baseline severe or greater TR)
- 68.1%
- 3-year mortality by residual TR at 30 days: Residual severe or greater TR 43.2%
- 3-year mortality by residual TR at 30 days: 30-day landmark analysis
Mortality by change in TR grade, baseline to 30 days
- Improvement in TR grade associated with lower mortality vs unchanged or worsened TR
Original publication
Tricuspid Regurgitation and 3-Year Mortality After Transseptal Mitral Valve-in-Valve Replacement. JACC Cardiovasc Interv. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →